FDA Reclassifies Bone Growth Stimulators, Raising Competitive and Margin Pressures for Orthofix Medical

Orthofix Medical Inc. (OFIX) has disclosed a new risk, in the Regulation category.

The FDA’s reclassification of bone growth stimulators from Class III to Class II is expected to lower regulatory barriers for new entrants, potentially intensifying competition against Orthofix Medical Inc.’s market‑leading PEMF and LIPUS platform. This shift could drive pricing pressure and increased rival marketing, ultimately weighing on Orthofix Medical Inc.’s sales, margins, and overall operating performance.

Overall, Wall Street has a Strong Buy consensus rating on OFIX stock based on 3 Buys and 1 Hold.

To learn more about Orthofix Medical Inc.’s risk factors, click here.